Structure-function studies of human FcRn
人FcRn的结构-功能研究
基本信息
- 批准号:7436166
- 负责人:
- 金额:$ 36.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-06-01 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAmino AcidsAntibodiesArtsBindingBiochemicalCellsCellular biologyComplexDataEndothelial CellsEpithelialEpithelial CellsGenerationsGoalsHomeostasisHumanHumoral ImmunitiesImage AnalysisImmune responseImmunoglobulin GImmunologic MonitoringIntestinesKidneyKnowledgeLeadLigandsLungMHC Class I GenesModelingMolecularMothersMusMutationPlayPre-Clinical ModelRattusRecyclingRodentRoentgen RaysRoleSerumSiteSpecificityStructureSystemTestingTherapeuticTissuesVariantbasefluorescence imagingimprovedneonatal Fc receptorprophylacticreceptortraffickingtranscytosis
项目摘要
DESCRIPTION (provided by applicant): The goal of this proposal is to gain an improved understanding at the molecular and cellular level of the human form of the MHC Class I-related receptor, FcRn. Recent data suggest that in addition to being the receptor that transports maternal immunoglobulin G (IgG) from mother to young, FcRn regulates the serum levels of IgG. IgG homeostasis is most likely maintained by FcRn expression in endothelial cells of the microvasculature. FcRn is also expressed in epithelial cells at diverse body sites (e.g. intestine, kidney and lung). FcRn transports IgG within (recycling) and across (transcytosis) cells, and is a protective receptor which salvages IgG from lysosomal degradation. Although human FcRn (hFcRn) and mouse FcRn (mFcRn) share about 65% amino acid identity, recent studies indicate that there are significant differences in IgG binding specificity. Intracellular trafficking studies of hFcRn and rat FcRn (highly homologous to mFcRn) suggest that there may also be variations at this level. As a result, studies in mice may not always be reliable indicators of hFcRn function. The current study is directed towards better understanding the similarities and differences between human and mouse FcRn. In turn, this should lead to improved knowledge of hFcRn. Our specific aims are: 1)To understand the molecular basis of the distinct binding specificity of hFcRn. 2) To assess the effects of IgG mutations on functional activity in mouse and human systems. 3) To analyze the intracellular trafficking of hFcRn in endothelial cells. Our studies are therefore directed towards addressing the fundamental question as to how hFcRn functions to maintain serum IgG levels, with a particular focus on hFcRn-lgG interactions and hFcRn trafficking in endothelial cells. This impacts the successful application of therapeutic and prophylactic IgGs, and also has broader relevance to the factors that regulate humoral immunity.
描述(由申请人提供):该提案的目的是在MHC I类相关受体FCRN的人类形式的分子和细胞水平上获得改进的理解。最近的数据表明,除了是将母体免疫球蛋白G(IgG)从母亲转移到年轻的受体外,FCRN还调节了IgG的血清水平。 IgG体内平衡很可能是通过微脉管系统内皮细胞中的FCRN表达来维持的。 FCRN在多种体位(例如肠,肾脏和肺)的上皮细胞中也表达。 FCRN在(回收)和(跨胞菌症)细胞内运输IgG,是一种保护性受体,可从溶酶体降解中挽救IgG。尽管人FCRN(HFCRN)和小鼠FCRN(MFCRN)具有约65%的氨基酸身份,但最近的研究表明,IgG结合特异性存在显着差异。 HFCRN和大鼠FCRN(与MFCRN高度同源)的细胞内运输研究表明,在此水平上也可能存在差异。结果,对小鼠的研究可能并不总是是HFCRN功能的可靠指标。当前的研究旨在更好地理解人和小鼠FCRN之间的相似性和差异。反过来,这应该导致对HFCRN的知识的提高。我们的具体目的是:1)了解HFCRN独特结合特异性的分子基础。 2)评估IgG突变对小鼠和人类系统功能活性的影响。 3)分析内皮细胞中HFCRN的细胞内运输。因此,我们的研究旨在解决HFCRN如何保持血清IgG水平的功能,特别关注内皮细胞中HFCRN-LGG相互作用和HFCRN运输。这影响了治疗和预防性IgG的成功应用,并且与调节体液免疫的因素具有更广泛的相关性。
项目成果
期刊论文数量(44)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Dual objective fluorescence microscopy for single molecule imaging applications.
用于单分子成像应用的双物镜荧光显微镜。
- DOI:10.1117/12.808259
- 发表时间:2009
- 期刊:
- 影响因子:0
- 作者:Ram,Sripad;Prabhat,Prashant;Ward,ESally;Ober,RaimundJ
- 通讯作者:Ober,RaimundJ
HOW ACCURATELY CAN A SINGLE MOLECULE BE LOCALIZED WHEN IMAGED THROUGH AN OPTICAL MICROSCOPE?
通过光学显微镜成像时,单个分子的定位精度如何?
- DOI:10.1109/isbi.2004.1398731
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:Ram,Sripad;Ward,ESally;Ober,RaimundJ
- 通讯作者:Ober,RaimundJ
Localizing single molecules in three dimensions - a brief review.
在三个维度上定位单个分子 - 简要回顾。
- DOI:10.1109/acssc.2008.5074362
- 发表时间:2008
- 期刊:
- 影响因子:0
- 作者:Ram,Sripad;Prabhat,Prashant;Chao,Jerry;Abraham,AnishV;Ward,ESally;Ober,RaimundJ
- 通讯作者:Ober,RaimundJ
Sedimentation equilibrium analysis of recombinant mouse FcRn with murine IgG1.
重组小鼠 FcRn 与鼠 IgG1 的沉降平衡分析。
- DOI:10.1016/s0161-5890(99)00093-0
- 发表时间:1999
- 期刊:
- 影响因子:3.6
- 作者:Schuck,P;Radu,CG;Ward,ES
- 通讯作者:Ward,ES
Quantitative study of single molecule location estimation techniques.
- DOI:10.1364/oe.17.023352
- 发表时间:2009-12-21
- 期刊:
- 影响因子:3.8
- 作者:Abraham AV;Ram S;Chao J;Ward ES;Ober RJ
- 通讯作者:Ober RJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ELIZABETH SALLY WARD其他文献
ELIZABETH SALLY WARD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ELIZABETH SALLY WARD', 18)}}的其他基金
2010 Antibody Biology and Engineering Gordon Research Conference
2010年抗体生物学与工程戈登研究会议
- 批准号:
7796947 - 财政年份:2010
- 资助金额:
$ 36.28万 - 项目类别:
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
7847559 - 财政年份:2008
- 资助金额:
$ 36.28万 - 项目类别:
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
7522511 - 财政年份:2008
- 资助金额:
$ 36.28万 - 项目类别:
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
8955602 - 财政年份:2008
- 资助金额:
$ 36.28万 - 项目类别:
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
7656698 - 财政年份:2008
- 资助金额:
$ 36.28万 - 项目类别:
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
8274344 - 财政年份:2008
- 资助金额:
$ 36.28万 - 项目类别:
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
8076708 - 财政年份:2008
- 资助金额:
$ 36.28万 - 项目类别:
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
7990253 - 财政年份:2008
- 资助金额:
$ 36.28万 - 项目类别:
相似国自然基金
成人型弥漫性胶质瘤患者语言功能可塑性研究
- 批准号:82303926
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
MRI融合多组学特征量化高级别成人型弥漫性脑胶质瘤免疫微环境并预测术后复发风险的研究
- 批准号:82302160
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
成人免疫性血小板减少症(ITP)中血小板因子4(PF4)通过调节CD4+T淋巴细胞糖酵解水平影响Th17/Treg平衡的病理机制研究
- 批准号:82370133
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
SMC4/FoxO3a介导的CD38+HLA-DR+CD8+T细胞增殖在成人斯蒂尔病MAS发病中的作用研究
- 批准号:82302025
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
融合多源异构数据应用深度学习预测成人肺部感染病原体研究
- 批准号:82302311
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Designing novel therapeutics for Alzheimer’s disease using structural studies of tau
利用 tau 蛋白结构研究设计治疗阿尔茨海默病的新疗法
- 批准号:
10678341 - 财政年份:2023
- 资助金额:
$ 36.28万 - 项目类别:
Mitochondrial electron transport dysfunction: Dissecting pathomechanisms
线粒体电子传递功能障碍:剖析病理机制
- 批准号:
10679988 - 财政年份:2023
- 资助金额:
$ 36.28万 - 项目类别:
Development and Production of Standardized Reference Diets for Zebrafish Research
斑马鱼研究标准化参考饲料的开发和生产
- 批准号:
10823702 - 财政年份:2023
- 资助金额:
$ 36.28万 - 项目类别:
A Potent D-peptide Inhibitor of TNFα for Treatment of Rheumatoid Arthritis
一种有效的 TNFα D 肽抑制剂,用于治疗类风湿性关节炎
- 批准号:
10822182 - 财政年份:2023
- 资助金额:
$ 36.28万 - 项目类别:
Exploiting Metabolism to Uncloak Epstein-Barr Virus Immunogens in Latently Infected B-cells
利用代谢揭示潜伏感染 B 细胞中的 Epstein-Barr 病毒免疫原
- 批准号:
10889325 - 财政年份:2023
- 资助金额:
$ 36.28万 - 项目类别: